

CHROMEDX REPORTS TESTING OF KEY HEMOPALM ANALYZER COMPONENT

TORONTO, ONTARIO -- (September 8, 2015) - ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that testing has commenced on the key spectroscopic component of the Analyzer of HemoPalm™ blood analysis device.

The spectroscopic analysis of blood samples is a key aspect of the HemoPalm system which significantly differentiates it from other point-of-care blood analyzers and replicates the testing methods seen in central laboratory benchtop devices.

Through the previously announced collaborative project with Dr. Cynthia Balion at McMaster University, calibration algorithms for the various hemoglobin (Hb) species referred to as CO-oximetry, are being developed using blood samples collected for the “Canadian Longitudinal Study on Aging”, in which Dr. Ballion is a key investigator. The microspectrometer used was supplied by Insion, Germany—the same microspectrometer that will be incorporated in the HemoPalm™ analyzer.

To date results for total hemoglobin (Total-Hb) and methhemoglobin (Met-Hb) have shown good correlation with FDA approved benchtop analyzer results. Testing and algorithm development continues for the other Hb species that will enable the HemoPalm™ to provide total CO-oximetry results. CO-oximetry measures the various hemoglobin (Hb) species present in the blood and is a critical and unique aspect of the HemoPalm™ compared to other point-of-care blood analyzers in the market. As an example, one of the Hb species is used to detect carbon monoxide poisoning.

During the CO-oximetry investigation, a calibration algorithm was developed for measurement of bilirubin in whole blood. Bilirubin is an indicator of jaundice and has particular importance in the prediction and treatment of neonatal jaundice.

“The progress shown in these two areas moves us closer to completion of the alpha prototype of the HemoPalm™ Analyzer system. Demonstration of the ability to measure bilirubin from whole blood in a hand-held analyzer with no sample preparation is a significant development in POCT. This provides the foundation for a second cartridge in the HemoPalm™ line and a potential second analyte market” said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.

The Company most recently announced the completion of the fabrication of the prototype HemoPalm™ cartridge, in conjunction with the McMaster Manufacturing Research Institute (MMRI). A complete archive of the Company’s news can be found on the ChroMedX website.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel

medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:

Facebook: facebook.com/ChroMedXcorp

Twitter: www.twitter.com/ChroMedXcorp

Investor Relations:

Shawn Overton

d. 647-528-9344

o. 647-872-9982 ext. 2

TF. 1-844-247-6633 ext. 2

soverton@ChroMedX.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.